0.45 (1.50%)

NASDAQ:ARVN | Last traded on 11-15-2019 4:00 PM

Market Reaction

Offer Price


Today Open Price


Change Since IPO

Market Cap


Day High


Day Low


View Stock Chart

Featured Analysis

Interesting. This is a company that I can also barely analyze. The biotech industry is one that I do not know. On the things I do know, it is a very tiny company that is going out to market very early relative to commercial viability. To me, this is a private equity play, not a public company play. If you know a lot about the status of their science and research, I would like to know more.

Company Data


New Haven, CT






Total Shares Offered





IPO Date


Background Information

Arvinas, Inc. is a biopharmaceutical company specializing in the research and development of treatments for the degradation of disease-causing proteins. Their products mainly target androgen receptors (AR) proteins in agents that cause diseases, such as metastatic prostate cancer, but they also produce treatments for different illnesses and with different functionalities.

Financial Analysis

Years 2016 2017
Revenue growth -- 14%
Net profit margin -215%-317%
Valuation -- $515M
Revenue multiple -- 64x
Profit multiple ---21x

Financial Information

Income Statement ($M) 2016 2017
Cost of goods sold2029
Gross profit(13)(21)
Total operating expense2332
Pretax profit(14)(24)
Net income(14)(24)
Balance Sheet ($M) 2016 2017
Total current assets3766
Cash and cash equivalents531
Total assets3867
Total current liabilities1018
Total liabilities1467
Total shareholder equity3361
Total liabilities and equity3867
Cash Flow Statement ($M) 20162017
Net cash from operating activities (19)5
Net cash from investing activities (20)21
Net cash from financing activities (150)(161)
Net increase in cash and cash equivalents (40)26